Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Reduced Intensity

Phase 2Small molecule

NNew York Medical College

1

Indications

5

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary T-Cell Immunodeficiency DisordersRecruiting

Primary T-Cell Immunodeficiency DisordersPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2036

Phase 2Recruiting

Primary T-Cell Immunodeficiency Disorders

NCT02579967

Clinical

Trials by Indication[1]

Non-malignant Disorders1 trial

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Completed·—·Phase 1·NCT00744692·22 enrolled

Conditioning1 trial

Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning

Completed·HHospices Civils de Lyon·Phase 2·NCT00466674·13 enrolled

Adult1 trial

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

Completed·NNew York Medical College·Phase 2·NCT01049854·20 enrolled

Lymphoma1 trial

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Unknown status·NNew York Medical College·Phase 1/2·NCT02098512·20 enrolled

Primary T-cell Immunodeficiency Disorders1 trial

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02579967·354 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Reduced Intensity. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Reduced Intensity compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Reduced Intensity. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNew York Medical College

Related News